Fig. 5: Relative associations of plasma biomarkers and brain atrophy and cognition in the validation cohort.
From: Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
Forest plots represent standardized β (colored dots) (βSTD) and 95% CI (black lines) from a multivariate model including all three plasma biomarkers as predictors. a–c, Analysis shown for tau-PET-positive individuals (a, cortical thickness: n = 159; early cognitive dysfunction: n = 143; global cognitive dysfunction: n = 160), Aβ-positive individuals (b, cortical thickness: n = 413; early cognitive dysfunction: n = 445; global cognitive dysfunction: n = 481) and all participants (c, cortical thickness: n = 522; early cognitive dysfunction: n = 556; global cognitive dysfunction: n = 593). Outcomes are listed on the left. Models were adjusted for age and sex (and education for cognitive outcomes). Vertical dashed lines indicate 0. Asterisks represent significant effect (P < 0.05) for each biomarker and model. Aβ status was assessed using CSF Aβ42/40 or Aβ-PET and tau status using global tau-PET (SUVR > 1.22). All tests were two sided.
